PAREXEL INTERNATIONAL TO PRESENT AT THE THOMAS WEISEL PARTNERS HEALTHCARE TAILWINDS CONFERENCE
BOSTON, MA, August 19, 2003 — PAREXEL International Corporation (Nasdaq: PRXL) announced today it would be presenting at the Thomas Weisel Partners Healthcare Tailwinds 2003 Conference at the Four Seasons Hotel in Boston, MA. Josef von Rickenbach, Chairman and Chief Executive Officer will be making a presentation on PAREXEL at 9:45 a.m. ET on Friday, September 5th.
The presentation will be broadcast live over the internet at http://www. parexel.com. To access the webcast, please visit the “Webcasts” page of the Investor Relations section of the Company’s website at least fifteen minutes prior to the scheduled presentation to register, download and install the necessary software. After the conference, the webcast will be archived and available for thirty days.
PAREXEL is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. The technology portfolio includes web-based portal solutions and tracking tools, Interactive Voice Response Systems (IVRS), Clinical Trial Management Systems (CTMS), electronic diary and investigator database solutions. Perceptive also offers advanced medical diagnostics services to assess rapidly and objectively the safety and efficacy of new drugs, biologics, and medical devices in clinical trials. PAREXEL’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 57 locations throughout 36 countries around the world, and has 5,095 employees.